stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
24.78
1.25
−4.80%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) EPS (diluted)
Caris Life Sciences,�Inc.'s EPS (diluted) for fiscal 2025 was −$3.22, compared with −$10.66 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.33. Caris Life Sciences,�Inc. ranks 51st of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.22 | — |
| FY2024 | −$10.66 | — |
| FY2023 | −$13.24 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.05 | — |
| Jun 2026 | $0.00 | — |
| Mar 2026 | $0.00 | — |
| Dec 2025 | $0.28 | 250.00% |
| 5 more quarters | Free account |
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $7.37 |
| TGTX TG Therapeutics, Inc. compare | $2.74 |
| PTGX Protagonist Therapeutics, Inc. compare | $1.03 |
| CAI Caris Life Sciences,�Inc. | $0.33 |
| IBRX ImmunityBio, Inc. compare | −$0.97 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| SYRE Spyre Therapeutics, Inc. compare | −$3.07 |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$5.98 |
| CYTK Cytokinetics, Incorporated compare | −$6.04 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on CAI
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement